Artemis Medicare Services Intrinsic Value
ARTEMISMED Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹91.20 | ₹72.96 - ₹109.44 | -66.4% | EPS: ₹7.60, Sector P/E: 12x |
| Book Value Method | asset | ₹602.86 | ₹542.57 - ₹663.15 | +122.0% | Book Value/Share: ₹602.86, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹543.20 | ₹488.88 - ₹597.52 | +100.0% | Revenue/Share: ₹805.71, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹543.20 | ₹488.88 - ₹597.52 | +100.0% | EBITDA: ₹232.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹679.00 | ₹543.20 - ₹814.80 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹81.48 | ₹73.33 - ₹89.63 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹81.48 | ₹73.33 - ₹89.63 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹543.20 | ₹488.88 - ₹597.52 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹321.07 | ₹288.96 - ₹353.18 | +18.2% | EPS: ₹7.60, BVPS: ₹602.86 |
Want to compare with current market value? Check ARTEMISMED share price latest .
Valuation Comparison Chart
ARTEMISMED Intrinsic Value Analysis
What is the intrinsic value of ARTEMISMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Artemis Medicare Services (ARTEMISMED) is ₹543.20 (median value). With the current market price of ₹271.60, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹81.48 to ₹679.00, indicating ₹81.48 - ₹679.00.
Is ARTEMISMED undervalued or overvalued?
Based on our multi-method analysis, Artemis Medicare Services (ARTEMISMED) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.81 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.61 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.83x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Artemis Medicare Services
Additional stock information and data for ARTEMISMED
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹146 Cr | ₹-47 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹109 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹127 Cr | ₹48 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹60 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹27 Cr | ₹9 Cr | Positive Free Cash Flow | 7/10 |